Bladder Cancer Studies Currently Recruiting Participants at the University of Chicago Medicine Comprehensive Cancer Center

Study Number Title
15550B Bladder Cancer Sample Collection
12278A Clinical Urology Research Screening Protocol
Select
11-0646 S1011: A Phase III Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radial Cystectomy for Muscle Invasive Urothelial Cancer
Select
IRB14-0894 A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 Administered Intravenously as a Single Agent to Patients with Locally Advanced or Metastatic Solid Tumors
Select
IRB14-0081 Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients with Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma
Select
IRB14-1429 A Phase 1 Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination with Tremelimumab (Anti-CTLA-4 Antibody) in Subjects with Advanced Solid Tumor
Select
IRB15-0630 A Phase III, Open-Label, Multicenter, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) Versus Observation as Adjuvant Therapy in Patients with PD-L1-Selected, High-Risk Muscle-Invasive Bladder Cancer After Cystectomy
Select
CIRB14-1105 S1314: A Randomized Phase II Study of Co-eXpression ExtrapolatioN (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
Select
IRB13-1410 A Phase 1/2, Placebo-Controlled, Randomized Study to Evaluate the Safety, Immune Response and Clinical Activity of HS-410 in Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Undergone Transurethral Resection of Bladder Tumor (TURBT) and Received Prior Treatment with Induction Bacille Calmette-Guerin (BCG)
Select
IRB14-1229 A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects with Advanced/Unresectable or Metastatic Urothelial Cancer
Select
CIRB14-1513 Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients with Advanced or Unresectable Urothelial Carcinoma of the Bladde
Select
IRB15-0266 An Open Label, Single Arm, Phase II, Multicenter Study of The Safety and Efficacy of CG0070 Oncolytic Vector Regimen in Patients With No-Muscle Invasive Bladder Carcinoma Who Have Failed BCG Therapy and Refused Cystectomy
Select
IRB15-1130 Phase I study of PD1 blockade by pembrolizumab with stereotactic body radiotherapy in advanced solid tumors
Select
IRB15-0703 A Phase II, Two-Arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a Pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects with Metastatic or Surgically Unresectable Urothelial Cancer with FGFR Genomic Alterations
Select
IRB15-1024 A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors

To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.
Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT team